Thermopylae Holdings Ltd. acquired a significant stake in AbCellera Biologics Inc. (ABCL) through an open market purchase. On February 27, 2026, the entity bought 177,457 shares of ABCL at an average price of $3.27 per share, representing a total investment of approximately $580,284.
This transaction adds to recent insider buying activity within AbCellera Biologics. Earlier on February 27, 2026, insider Andrew Booth also purchased 42,600 shares, valued at roughly $145,692. Insider purchases are often viewed by the market as a positive indicator of management's confidence in the company's future prospects.